Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of MEDI9929 in adult moderate-to-severe atopic dermatitis
2015-000595-10Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing MEDI9929 with Placebo (2 arms). Primary endpoint: EASI-50 response at Week 12. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2015-000595-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000595-10.